-
EClinCloud Secures New Funding to Accelerate AI Innovation in Clinical Research
•
EClinCloud (Ningbo) Technology Co., Ltd., a leading AI technology company specializing in clinical research solutions, has announced the completion of a new round of financing worth tens of millions of yuan. The investment was exclusively led by Hongfeng, a renowned biopharmaceutical investment firm. This funding will further accelerate EClinCloud’s deep…
-
Shanghai RAAS Plans RMB4.2 Billion Acquisition of Nanyue BioPharming to Boost Plasma Resources
•
China’s Shanghai RAAS (SHE: 002252) has announced plans to acquire 100% stakes in compatriot firm Nanyue BioPharming Co., Ltd, one of the first blood products companies in the country, for RMB4.2 billion (USD578 million) in cash. The acquisition aims to ramp up RAAS’ plasma resources and high-quality production base. Acquisition…
-
Johnson & Johnson Pledges USD55 Billion for US Expansion, Focusing on Manufacturing and R&D
•
US giant Johnson & Johnson (J&J, NYSE: JNJ) has committed to investing over USD 55 billion over the next four years in the United States, allocated to manufacturing, research and development, and technology. This represents a 25% increase compared to the previous four years, building on the company’s increased investment…
-
Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development
•
China-based Harbour BioMed (HKG: 2142) has formed a strategic partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN) to discover and develop next-generation multi-specific antibodies for immunology, oncology, and beyond. The collaboration grants AstraZeneca an option to license multiple programs utilizing Harbour BioMed’s proprietary Harbour Mice fully human antibody technology platform…
-
Celregen Therapeutics Secures RMB100 Million for iPSC Regenerative Medicine Platform
•
Hangzhou-based Celregen Therapeutics, a specialist in cell stem regenerative medicine incubated by Fosun Health Capital, announced the completion of an angel+ financing round, raising close to RMB100 million (USD13.8 million). The funding was led by Fosun Health Capital and SciNova Investment, with proceeds allocated to constructing the company’s iPSC regenerative…
-
Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline
•
Accropeutics Inc., a clinical-stage biotech company with operations in New York, US, and Suzhou, China, announced the completion of a Series B+ financing round, raising close to RMB100 million (USD13.8 million). The round was led by Shenzhen Capital Group (SCGC) and included contributions from Morningside Ventures, Leader Venture Capital, and…
-
Rona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies
•
Shanghai-based Rona Therapeutics announced the successful completion of a $25 million (RMB 180 million) Pre-B financing round. This funding will accelerate the development of the company’s proprietary delivery and chemical modification platform technologies and expand its siRNA clinical pipeline in cardiovascular metabolic, weight loss, and other therapeutic areas. Investor Support…
-
Insilico Medicine Closes USD110 Million Series E Round to Advance AI-Driven Drug Pipeline
•
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced the completion of a USD110 million Series E financing round. The round was led by a private equity fund of Value Partners Group (HKG: 0806), with participation from Shanghai Pudong Venture Investment, Shanghai Pudong Development (Group), Wuxi Innovation Investment, and Yixing…
-
Newdel Biotech Secures A+ Round Funding to Accelerate DEL+AI-Driven Drug Discovery
•
Newdel Biotech recently announced the completion of an A+ round strategic investment led by XtalPi Holdings Limited (HKG: 2228), a global leader in AI+ automation technology platforms. This investment will fuel the deep integration of Newdel Biotech’s DNA-encoded compound library (DEL) technology with XtalPi’s AI platform, aiming to accelerate the…
-
Juvensis Therapeutics Secures RMB100 Million for Heart Gene Therapy Development
•
Shanghai-based Juvensis Therapeutics, a specialist in anti-aging therapies, reportedly raised upwards of RMB100 million (USD13.8 million) via a Pre-Series A financing round. Led by Growth FoF, the funding included contributions from Nanjing Jiangbei New Area Sci-tech Investment Group, Henry WU, and Shanghai Healthcare Capital, among others. The proceeds will be…
-
Sichuan Biokin Pharmaceutical Plans RMB3.9 Billion Private Placement for Novel Drug R&D
•
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced plans to raise up to RMB3.9 billion (USD537 million) through a private placement. The funds will be allocated to various novel drug research and development programs, furthering the company’s commitment to innovation in the biopharmaceutical sector. Funding AllocationThe proceeds from the…
-
Sansure Biotech Plans RMB130 Million Investment in Shenzhen GeneMind for Gene Sequencing Expansion
•
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) announced plans to invest RMB130 million (USD17.9 million) in compatriot firm Shenzhen GeneMind Biosciences Co., Ltd., a gene sequencer specialist. This investment aims to enhance Sansure’s industry chain layout in the gene sequencing sector and boost its comprehensive competitiveness. Transaction DetailsThe…
-
Sun Pharma to Acquire Checkpoint Therapeutics for USD355 Million, Focusing on Cancer Immunotherapy
•
India-based Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) announced plans to acquire all outstanding shares of US-headquartered Checkpoint Therapeutics (NASDAQ: CKPT) for USD4.1 per share, totaling USD355 million. As part of the deal, Checkpoint shareholders will receive a contingent value right (CVR) entitling them to up to USD0.70 per share, contingent…
-
NewCo Model: China’s Innovative Drug Companies’ New Transaction Mode in Capital Winter
•
NewCo is a new transaction model developed by Chinese innovative drug companies in response to capital winter and internationalization needs. It involves licensing overseas rights of early-stage R&D pipelines to newly established independent companies, bringing in overseas capital and management teams to accelerate development and share risks. This model combines…
-
Hangzhou Chance Pharmaceuticals Secures New Funding for Inhalation Powder Aerosol Development
•
Hangzhou Chance Pharmaceuticals recently announced the completion of a new funding round, led by Zhejiang’s “4+1” Biomedical and High-end Medical Device Industry Fund and Qihang Investment Management Co., Ltd., with Lighthouse Capital serving as the exclusive financial advisor. The funds will propel the Phase III clinical trial of CXG87, a…
-
4C Medical Lands $175M Series D to Advance AltaValve TMVR System
•
US-based 4C Medical Technologies, Inc., a medical device company controlled by China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), announced the completion of a $175 million Series D financing round. The funding, led by Boston Scientific Corporation, will accelerate clinical development and commercialization of 4C Medical’s AltaValve System, a next-generation…
-
Jiangsu Nhwa Pharmaceutical Invests in NeuroThree to Develop CNS Therapies
•
China-based Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262) announced plans to subscribe to Hong Kong-headquartered NeuroThree Therapeutics, Inc.’s Pre-Series A financing round, investing USD 3.5 million for 12.5 million shares. Upon completion of the transaction, Nhwa will hold a 10.448% stake in NeuroThree. Company BackgroundFounded in 2021, NeuroThree focuses on…
-
Danatlas Raises RMB 150M to Advance Synthetic Lethality Drug Pipeline
•
Beijing-headquartered Danatlas, a first-in-class drug developer in the synthetic lethality field, has reportedly raised RMB 150 million (USD 21 million) in a new financing round. The round was led by Bayland Capital and included contributions from AstraZeneca-CICC Health Industry Investment Fund, Growth Investment, Panlin Capital, and returning investor Sequoia Capital.…
-
Pulnovo Medical Raises USD 100M in Series C Financing for Global Expansion
•
Wuxi-based Pulnovo Medical Limited, a developer of medical devices for pulmonary hypertension and heart failure, has reportedly raised nearly USD 100 million in a Series C financing round. The funding was led by Qiming Venture Partners and Lilly Asia Ventures, with contributions from returning investors OrbiMed and Gaorong Capital. Company…
-
Biointron Biologics Files for Public Offering, Aims for BSE Listing
•
On February 11, Biointron Biologics released its tutoring filing report for the public offering of shares to unspecified qualified investors and listing on the Beijing Stock Exchange (BSE). The tutoring work is led by Haitong Securities Co., Ltd., with Grandway Law Offices and Grant Thornton China (Special General Partnership) responsible…
